Dexamethasone- and prednisone-based regimens are part of the conventional and new methods to treat newly diagnosed or recurrent/multiple myeloma, These medications raise blood glucose through increased insulin resistance, gluconeogenesis, glycogenolysis, and decreased insulin production and secretion [20]. This evidence concerns the gene INS and AL amyloidosis.